UPDATE: Celera s Acquisition of Axys Seen Boosting Drug Discovery Effort | GenomeWeb

This article has been updated from a previous version.

NEW YORK, June 13 - Celera Genomics announced its intention Wednesday to acquire Axys Pharmaceuticals in a stock transaction valued at $173.4 million, making good on its promise to purchase a company with chemistry and drug design capabilities. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic link between birth weight and adult-onset diseases, and more.

Even with all the current enthusiasm for gene therapies, Tech Review cautions that they are mostly in the early stages of development.

DNA phenotyping puts a potential face to a suspect in a nearly 25-year-old murder, the AP reports.

Researchers discuss the need for antibody standards at a meeting, NPR reports.